Page 309 - Drug Class Review
P. 309
Drug Effectiveness Review Project
Drugs Authors: Erkinjuntti et al. 90 Country: Multinational (10 countries) Janssen Research Foundation To determine the effect of GAL on patients with probable VaD or AD combined with CVD Setting: Multi-center (number of centers NR) placebo galantamine N/A 24 mg/d 6 months 6 months 196 396 Met clinical criteria for probable VaD based on NINDS-AIREN guidelines or AD based on NINCDS/ADRDA; significant radiological evidence of CVD; MMSE score of 10-25: ADAS-Cog score > 12; have a reliable caregiver; evidence of relevant focal neurological signs consistent with previous
Alzheimer Year: 2002 Study design: RCT Sample size: 592 stroke or CVD
Final Report Update 1 Subgroups STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
